Silver Book Fact

Lucentis to treat wet age-related macular degeneration (AMD)

An FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)–ranibizumab (Lucentis)–maintained vision in 95% of clinical trial participants and improved vision by 15 or more letters in approximately 25% to 34% of trial participants.

Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for Neovascular Age-Related Macular Degeneration. NEJM. 2006; 355(14): 1419-31. http://content.nejm.org/cgi/content/abstract/355/14/1419

Reference

Title
Ranibizumab for Neovascular Age-Related Macular Degeneration
Publication
NEJM
Publication Date
2006
Authors
Rosenfeld PJ, Brown DM, Heier JS, et al
Volume & Issue
Volume 355, Issue 14
Pages
1419-31
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Multifocal electroretinogram (mFERG) and flicker perimetry show abnormal function in the central macula in early ag-related macular degeneration (AMD) and could enhance monitoring of the disease progression in individuals.  
  • High-intensity ultrasonic cyclocoagulation reduces intraocular pressure in refractory glaucoma patients.  
  • Current treatments for proliferative diabetic retinopathy have reduced the rate of blindness within 5 years from 50% to less than 5%.  
  • Intensive Glycemic Control in People with Diabetes
    Intensive glycemic control in diabetics reduced their: Adjusted mean risk of DR by 76% Risk of progression by 54% Rates of laser surgery by 56% Risk of DME by 23%    
  • The cost-effectiveness of detection and treatment of eye disease in diabetics is $3,190 per quality adjusted life year (QALY).